Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
10
pubmed:dateCreated
2003-10-7
pubmed:abstractText
Left ventricular (LV) systolic function in hypertrophic cardiomyopathy (HCM) is usually normal. Late in the disease, however, LV systolic dysfunction and dilatation are recognized. Although abnormalities in cardiac sympathetic nerve activity in patients with HCM have been demonstrated using (123)I-metaiodobenzylguanidine (MIBG) myocardial scintigraphy, the changes of cardiac sympathetic nerve activity throughout the clinical course from typical to end-stage HCM are unclear. The objective of this study was to evaluate the relationship between abnormalities on (123)I-MIBG myocardial scintigraphy and pathophysiologic changes in patients with HCM.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Oct
pubmed:issn
0161-5505
pubmed:author
pubmed:issnType
Print
pubmed:volume
44
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1612-7
pubmed:dateRevised
2004-11-17
pubmed:meshHeading
pubmed-meshheading:14530475-3-Iodobenzylguanidine, pubmed-meshheading:14530475-Adult, pubmed-meshheading:14530475-Aged, pubmed-meshheading:14530475-Cardiomyopathy, Hypertrophic, pubmed-meshheading:14530475-Female, pubmed-meshheading:14530475-Heart Ventricles, pubmed-meshheading:14530475-Humans, pubmed-meshheading:14530475-Male, pubmed-meshheading:14530475-Metabolic Clearance Rate, pubmed-meshheading:14530475-Middle Aged, pubmed-meshheading:14530475-Myocardium, pubmed-meshheading:14530475-Radiopharmaceuticals, pubmed-meshheading:14530475-Reference Values, pubmed-meshheading:14530475-Reproducibility of Results, pubmed-meshheading:14530475-Sensitivity and Specificity, pubmed-meshheading:14530475-Single-Blind Method, pubmed-meshheading:14530475-Sympathetic Nervous System, pubmed-meshheading:14530475-Ventricular Dysfunction, Left
pubmed:year
2003
pubmed:articleTitle
Changes in cardiac sympathetic nerve innervation and activity in pathophysiologic transition from typical to end-stage hypertrophic cardiomyopathy.
pubmed:affiliation
Molecular Genetics of Cardiovascular Disorders, Division of Cardiovascular Medicine, Kanazawa University, Kanazawa, Japan. yonken1@med.kanazawa-u.ac.jp
pubmed:publicationType
Journal Article, Clinical Trial, Controlled Clinical Trial